Overactive Bladder: Global Drug Forecast and Market Analysis to 2030

Pages: 130 Published: December 14, 2021 Report Code: GDHC231PIDR

  • Overview
  • Key Players
  • Contents
  • Tables
  • Figures
  • FAQ
  • Listen
    https://www.ispeech.org/text.to.speech

The overactive bladder (OAB) market sales have been valued at $2.2 billion in 2020 across the eight major markets (8MM) covered in this report- the US, 5EU (France, Germany, Italy, Spain, and the UK), Japan and China. The market is projected to grow at a CAGR of more than 2% during the period 2021-2030. The US accounted for the largest market with global sales in 2020, equating to a market share of more than 45%. This largely reflects the large prevalence population in the US and the high cost of drug therapy in this market. Myrbetriq is currently the leading OAB therapy with global sales in 2020, equating to a market share of more than 50%.

The considerable growth expected during the mid-to-late forecast period reflects a continued trend for increased OAB prevalence, as well as the anticipated launch of several pipeline agents. As previously discussed, the late-stage pipeline is scarce with no products in Phase III development or the Pre-registration stage of development although there are a limited number of products in Phase II development.

Overview of the overactive bladder market

Overview of the overactive bladder market

For more insights on this report, download a free report sample

What are the market dynamics in the OAB drug market?

The major drivers of market growth over the forecast period are the continued uptake of the beta-3 agonist Gemtesa (marketed as Beova in Japan) in Japan and the US and the potential launch of this product in China, The potential launch of pipeline agents in the mid-to-late forecast period. These include Bayer’s P2X purinoceptor 3 (P2RX3) antagonist Eliapixant in the global market, Urovant Sciences’ gene therapy URO-902 in the US market, and Taiho Pharmaceuticals’ neurite outgrowth enhancer TAC 302 in the Japanese market. All these products employ novel mechanisms of action and are currently in Phase II development and increase in the prevalence of OAB over the forecast period owing to trends such as aging populations and rising obesity, leading to an increase in the population of diagnosed prevalent cases.

Generic sales erosion of VESIcare, Myrbetriq, and Toviaz due to recent and upcoming patent expirations in key markets, including the US.  The scarcity of the late-stage pipeline. In particular, the lack of drugs in Phase III development or the pre-registration stages of development will restrict market growth over the early-to-mid forecast period. Moreover, factors that contribute to low rates of diagnosis and treatment are expected to persist over the forecast period. These include stigma and misinformation surrounding OAB, which deters patients from seeking medical help, as well as poor persistence and adherence to drug therapy. The major barriers to market growth over the forecast period are the factors which contribute to low rates of diagnosis and treatment are expected to persist over the forecast period. These include stigma and misinformation surrounding OAB, which deters patients from seeking medical help, as well as poor persistence and adherence to drug therapy.

What are the diagnosed incident cases of OAB in the 8MM?

In 2020, China accounted for more than 60% of the total prevalent cases of OAB in the 8MM, with 222,928,413 cases, while the US accounted for more than 15% of the total prevalent cases of overactive bladder with 68,942,473 cases. There were more than 15% of the total prevalent cases in the 5EU, while Japan had more than 4% of cases. In the 8MM, the total prevalent cases of OAB will grow by more than 10% over the forecast period at an Annual Growth Rate (AGR) of more than 1%, from 363,318,429 cases in 2020. Of the 8MM, China is expected to have the highest AGR of more than 1%. Spain had the lowest number of total prevalent cases of OAB in 2020. Any change in the total prevalent cases of OAB is attributable to changing population demographics in the 8MM.

Diagnosed incident cases of OAB in the 8MM, by country

Diagnosed incident cases of OAB in the 8MM, by country

For more regional insights, download a free report sample

Which are the major players in the OAB drug market?

The major players in the market are Allergan, Astellas, Pfizer, Urovant Sciences, Bayer, Taiho Pharmaceuticals and Kyorin Pharmaceutical.

OAB drug market, by key players

OAB drug market, by key players

For more insights on key players, download a free report sample

Market report scope

Market size (Year – 2020) $2.2 billion
Growth rate (CAGR) >2%
Base year 2020
Forecast Period 2021-2030
Key Countries The US, 5EU (France, Germany, Italy, Spain, and the UK)
Key Players Allergan, Astellas, Pfizer, Urovant Sciences, Bayer, Taiho Pharmaceuticals and Kyorin Pharmaceuticals

Scope

This report provides an in-depth analysis of the following:

  • Overview of OAB, including classification, epidemiology, etiology, pathophysiology, diagnosis, and disease management.
  • Topline OAB therapeutics market revenue for 2020-2030 (includes the annual cost of therapy and anticipated sales for major late-stage pipeline drugs).
  • Key topics covered include current treatment options, clinical trials landscape, unmet needs and opportunities, R&D strategies, drivers and barriers of market growth, current and future players, and market outlook.
  • Pipeline analysis: Emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
  • Analysis of the current and future market competition in the global OAB drug market. Insightful review of the key industry drivers, constraints, and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.

Reasons to Buy

The report will enable you to:

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most promising pipeline assets.
  • Develop business strategies by understanding the trends shaping and driving the global OAB drug market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global OAB drug market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Key Players

Allergan, Astellas, Bayer, DelNova, Dompe Farmaceutici, Dong-A ST Co., Ion Channel Innovations, Johnson & Johnson, Kissei Pharmaceutical, Korea United Pharm, Kyorin Pharmaceutical, Merck & Co, Mezzion Pharma, Pfizer, Roivant Sciences, Sinovant Sciences, Sinsin Pharmaceutical, Taiho Pharmaceuticals, TARIS Biomedical, Urovant Sciences, Viatris, XuanZhu Biological Technology Co.

Table of Contents

| Contents

| List of Tables

| List of Figures

| About GlobalData

1 Overactive Bladder: Executive Summary

1.1 Overactive Bladder Market to Experience Moderate Growth, Reaching $2.8 Billion by 2030

1.2 R&D Landscape Shifts Away from Orally Administered Antimuscarinics

1.3 Significant Unmet Needs to Persist Throughout Forecast Period

1.4 Urovant Sciences Has Potential to Launch the First Gene Therapy in Overactive Bladder

1.5 What Do Physicians Think?

2 Introduction

2.1 Catalyst

2.2 Related Reports

3 Disease Overview

3.1 Etiology and Pathophysiology

3.1.1 Etiology

3.1.2 Pathophysiology

3.2 Classification or Staging Systems

4 Epidemiology

4.1 Disease Background

4.2 Risk Factors and Comorbidities

4.3 Global and Historical Trends

4.4 8MM Forecast Methodology

4.4.1 Sources

4.4.2 Forecast Assumptions and Methods

4.4.3 Forecast Assumptions and Methods: Total Prevalent Cases of OAB

4.4.4 Forecast Assumptions and Methods: Total Prevalent Cases of OAB by Presentation

4.4.5 Forecast Assumptions and Methods: Total Prevalent Cases of OAB by Comorbidity

4.4.6 Diagnosed Prevalent Cases of OAB

4.5 Epidemiological Forecast for OAB (2020–2030)

4.5.1 Total Prevalent Cases of OAB

4.5.2 Age-Specific Total Prevalent Cases of OAB

4.5.3 Sex-Specific Total Prevalent Cases of OAB

4.5.4 Total Prevalent Cases of OAB by Presentation

4.5.5 Total Prevalent Cases of OAB by Comorbidity

4.5.6 Diagnosed Prevalent Cases of OAB

4.5.7 Age-Specific Diagnosed Prevalent Cases of OAB

4.5.8 Sex-Specific Diagnosed Prevalent Cases of OAB

4.5.9 Diagnosed Prevalent Cases of OAB by Presentation

4.5.10 Diagnosed Prevalent Cases of OAB by Comorbidity

4.6 Discussion

4.6.1 Epidemiological Forecast Insight

4.6.2 COVID-19 Impact

4.6.3 Limitations of the Analysis

4.6.4 Strengths of the Analysis

5 Disease Management

5.1 Diagnosis and Treatment Overview

5.2 KOL Insights on Disease Management

6 Competitive Assessment

6.1 Overview

7 Unmet Needs and Opportunity Assessment

7.1 Overview

7.2 Insufficient Understanding of Pathophysiological Mechanisms Underlying OAB Subtypes and Lack of Targeted Therapies

7.3 Low Diagnosis Rates

7.4 Efficacy Limitations of Marketed Drugs

7.5 Safety and Tolerability Limitations of Marketed Drugs

7.6 Poor Persistence and Adherence to Drug Treatment

8 R&D Strategies

8.1 Overview

8.1.1 Reliance on Strategic Alliances, Mergers, and Acquisitions

8.1.2 Investment in Novel Molecular Targets and Mechanisms of Action

8.1.3 Alternative Routes of Administration

8.2 Clinical Trials Design

8.2.1 Clinical Trial Protocol

8.2.2 Patient Recruitment

8.2.3 Clinical Trial Endpoints

9 Pipeline Assessment

9.1 Overview

9.2 Late-stage Drugs in Clinical Development

9.2.1 Gene Therapy

9.2.2 P2RX3 Antagonist

9.2.3 Neurite Outgrowth Enhancer

10 Pipeline Valuation Analysis

10.1 Overview

10.2 Competitive Assessment

10.2.1 Second-Line Therapy

10.2.2 Third-Line Therapy

11 Current and Future Players

11.1 Overview

11.2 Astellas Pharma

11.3 Pfizer

11.4 Urovant Sciences

11.5 Bayer

11.6 Taiho Pharmaceutical

11.7 Allergan

11.8 Kyorin Pharmaceutical

12 Market Outlook

12.1 Global Markets

12.1.1 Forecast

12.1.2 Drivers and Barriers – Global Issues

12.2 US

12.2.1 Forecast

12.2.2 Key Events

12.2.3 Drivers and Barriers

12.3 5EU

12.3.1 Forecast

12.3.2 Key Events

12.3.3 Drivers and Barriers

12.4 Japan

12.4.1 Forecast

12.4.2 Key Events

12.4.3 Drivers and Barriers

12.5 China

12.5.1 Forecast

12.5.2 Key Events

12.5.3 Drivers and Barriers

13 Appendix

13.1 Bibliography

13.2 Abbreviations

13.3 Methodology

13.3.1 Forecasting Methodology

13.4 Primary Research – KOLs Interviewed for This Report

13.4.1 KOLs

13.5 Primary Research – Prescriber Survey

13.6 About the Authors

13.6.1 Analyst

13.6.2 Therapy Area Director

13.6.3 Epidemiologist

13.6.4 Managing Epidemiologist

13.6.5 Global Director of Therapy Analysis and Epidemiology

13.6.6 Global Head and EVP of Healthcare Operations and Strategy

| Contact Us

List of Tables

Table 1: Overactive Bladder: Key Metrics in the 8MM

Table 2: Risk Factors and Comorbidities for Overactive Bladder

Table 3: Total Prevalent Cases of OAB by Comorbidity

Table 4: Diagnosed Prevalent Cases of OAB by Comorbidity

Table 5: Treatment Guidelines for Overactive Bladder

Table 6: Astellas’ Overactive Bladder Portfolio Assessment, 2021

Table 7: Pfizer’s Overactive Bladder Portfolio Assessment, 2021

Table 8: Urovant’s Overactive Bladder Portfolio Assessment, 2021

Table 9: Bayer’s Overactive Bladder Portfolio Assessment, 2021

Table 10: Taiho’s Overactive Bladder Portfolio Assessment, 2021

Table 11: Allergan’s Overactive Bladder Portfolio Assessment, 2021

Table 12: Kyorin Pharmaceutical’s Overactive Bladder Portfolio Assessment, 2021

Table 13: Overactive Bladder Market – Global Drivers and Barriers, 2020–2030

Table 14: Key Events Impacting Sales for OAB in the US, 2020–2030

Table 15: OAB Market – Drivers and Barriers in the US, 2020–2030

Table 16: Key Events Impacting Sales for OAB in the 5EU, 2020–2030

Table 17: OAB Market – Drivers and Barriers in the 5EU, 2020–2030

Table 18: Key Events Impacting Sales for Overactive Bladder in Japan, 2020–2030

Table 19: Overactive Bladder Market – Drivers and Barriers in Japan, 2020–2030

Table 20: Key Events Impacting Sales for OAB in China, 2020–2030

Table 21: Overactive Bladder Market – Drivers and Barriers in China, 2020–2030

Table 22: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures

Figure 1: Global Sales Forecast by Country for Overactive Bladder in 2020 and 2030

Figure 2: 8MM, Total Prevalence of OAB, Men and Women, %, Ages ≥5 Years, 2020

Figure 3: 8MM, Diagnosed Prevalence of Overactive Bladder, Men and Women, %, Ages ≥5 Years, 2020

Figure 4: 8MM, Sources Used and Not Used to Forecast the Total Prevalent Cases of OAB

Figure 5: 8MM, Sources Used to Forecast the Total Prevalent Cases of OAB by Presentation

Figure 6: 8MM, Sources Used to Forecast the Total Prevalent Cases of OAB by Comorbidity

Figure 7: 8MM, Total Prevalent Cases of Overactive Bladder, N, Both Sexes, Ages ≥5 Years, 2020

Figure 8: 8MM, Total Prevalent Cases of OAB by Age, N, Both Sexes, 2020

Figure 9: 8MM, Total Prevalent Cases of OAB by Sex, N, Ages ≥5 Years, 2020

Figure 10: 8MM, Total Prevalent Cases of OAB by Presentation, N, Both Sexes, Ages ≥5 Years, 2020

Figure 11: 8MM, Diagnosed Prevalent Cases of OAB, N, Both Sexes, Ages ≥5 Years, 2020

Figure 12: 8MM, Diagnosed Prevalent Cases of OAB by Age, N, Both Sexes, 2020

Figure 13: 8MM, Diagnosed Prevalent Cases of OAB by Sex, N, Ages ≥5 Years, 2020

Figure 14: 8MM, Diagnosed Prevalent Cases of OAB by Presentation, N, Both Sexes, Ages ≥5 Years, 2020

Figure 15: Overactive Bladder Treatment Algorithm

Figure 16: Unmet Needs and Opportunities in OAB

Figure 17: Overview of the Development Pipeline in OAB

Figure 18: Key Late-Stage Trials for the Late-Stage Pipeline Agents that Have Potential to be Licensed for OAB in the 8MM During the Forecast Period

Figure 19: Competitive Assessment of the Pipeline Drugs in the Second-line Therapy Setting Benchmarked Against the SOC, Myrbetriq

Figure 20: Competitive Assessment of the Pipeline Drugs in the Third-Line Therapy Setting Benchmarked Against the SOC, Botox

Figure 21: Global (8MM) Sales Forecast by Country for Overactive Bladder in 2020 and 2030

Figure 22: Sales Forecast by Drug Class for Overactive Bladder in the US in 2020 and 2030

Figure 23: Sales Forecast by Drug Class for Overactive Bladder in the 5EU in 2020 and 2030

Figure 24: Sales Forecast by Drug Class for Overactive Bladder in Japan in 2020 and 2030

Figure 25: Sales Forecast by Drug Class for Overactive Bladder in China in 2020 and 2030

Frequently Asked Questions

The overactive bladder (OAB) market was valued at $2.2 billion in 2020.

 

 

 

The overactive bladder (OAB) market is projected to grow at a CAGR of more than 2% during 2021-2030.

In 2020, China accounted for more than 60% of the total prevalent cases of OAB in the 8MM.

The major players in the market are Allergan, Astellas, Pfizer, Urovant Sciences, Bayer, Taiho Pharmaceuticals and Kyorin Pharmaceuticals.

$10995

Can be used by individual purchaser only

$32985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.